Skip to content
DataLookout
Menu

NCT05868876

A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

StatusCompleted
PhasePhase 1
SponsorAkeso
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 2 words Show 7 more changesShow less
    • Trial completed
    • Final enrollment: 70 participants (planned 205)
    • Primary completion date changed from estimate of Nov 2025 to Mar 4, 2026
    • Start date: Jun 29, 2023 to Jul 26, 2023
    • Interventions: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion (Drug) to AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion (Drug)
    • Secondary endpoints: details revised at 1 of 14 entries
    • Site details revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 3, 2023 to Jun 29, 2023
    • Study title expanded, about 12 words
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence and severity of adverse events(AE);
Timeframe: Up to approximately 2 years
Incidence of serious adverse events(SAE);
Timeframe: Up to approximately 2 years
Incidence of immune-related adverse events(irAE);
Timeframe: Up to approximately 2 years
The incidence of suspected unexpected serious adverse reactions(SUSAR);
Timeframe: Up to approximately 2 years
Incidence of dose-limiting toxicity(DLT);
Timeframe: Up to approximately 2 years
Number of participants with clinically significant changes in laboratory assessment data as assessed by CTCAE v5.0.
Timeframe: Up to approximately 2 years
AE that leads to the termination or suspension of treatment.
Timeframe: Up to approximately 2 years

Secondary (14)

Objective response rate(ORR)
Disease control rate(DCR)
duration of response(DoR)
time to response(TTR)
progression-free survival(PFS)
Show 9 moreShow less
overall survival(OS)
The drug concentration of AK127 and AK104 in serum
maximum concentration(Cmax)of AK127 and AK104 in serum
peak time(Tmax) of AK127 and AK104 in serum
half time(t1/2) of AK127 and AK104 in serum
area under curve(AUC)of AK127 and AK104 in serum
clearance rate(CL) of AK127 and AK104 in serum
apparent volume of distribution(Vd) of AK127 and AK104 in serum
Number and percentage of subjects with anti-drug antibody(ADA) to AK127 and AK104

Arms and interventions

The dose escalation stage, dose expansion stage of AK127 combination with AK104Experimental

The dose escalation stage: 5 dose groups were set up, which were 0.3mg/kg、1 mg/kg, 3 mg/kg, 7.5 mg/kg, 15 mg/kg Q3W in dose escalation stage; The dose expansion stage: 8 cohorts with different indications were included in each group with 10-20 subjects in dose expansion stage.

Drugs: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion

Sites

1 site in 1 country

  • Tianjin Cancer HospitalTianjin, Tianjin Municipality, China